Inner ear involvement in Anderson-Fabry disease: Long-term follow-up during enzyme replacement therapy;Risultati a lungo termine della terapia sostitutiva sulle manifestazioni audio-vestibolari della malattia di Anderson-Fabry

Acta Otorhinolaryngologica Italica

Volumn 30, Issue 2, 2010, Pages 87-93

  Sergi, B ^a   Conti, G ^a   Paludetti, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

galactosidase a; Enzyme replacement therapy; Fabry disease; Inner ear; Sensorineural hearing loss; Vestibular damage

Indexed keywords

ALPHA GALACTOSIDASE;

ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE COURSE; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; FOLLOW UP; HUMAN; INNER EAR DISEASE; MALE; MIDDLE AGED; TIME;

ADOLESCENT; ADULT; AGED; ALPHA-GALACTOSIDASE; DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LABYRINTH DISEASES; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 77953298129     PISSN: 0392100X     EISSN: 1827675X     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Schriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular basis of inherited disease. Vol. 3, 8th edition. New York: McGraw-Hill 2001. p. 3733-74.
2. Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
3. Schachern PA, Shea DA, Paparella MM, et al. Otologic histopathology of Fabry's disease. Ann Otol Rhinol Laryngol 1989;98:359-63.
4. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-60.
5. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-75.
6. Germain DP, Avan P, Chassaing A, et al. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet 2002;3:10-20.
7. Conti G, Sergi B. Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females. Acta Paediatr Suppl 2003;92:33-7.
8. Hajioff D, Enever Y, Quiney R, et al. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 2003;26:787-94.
9. Hegemann S, Hajioff D, Conti G, et al. Hearing loss in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 2006;36:654-62.
10. Hajioff D, Hegemannn S, Conti G, et al. Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 2006;36:663-7.
11. Katz J. Handbook of clinical audiology. Philadelphia: Lippincott, Williams & Wilkins 2002
12. Hughes GB, Freedman MA, Haberkamp TJ, et al. Sudden sensorineural hearing loss. Otolaryngol Clin North Am 1996;29:393-405.
13. Sergi B, Conti G. Hearing loss in a family affected by Fabry disease. J Inherit Metab Dis 2007;30:370-4.
14. Kodama K, Kobayashi H, Abe R, et al. A new case of α-N-acetylgalactosaminidase deficiency with angiokeratoma corporis diffusum, with Meniere's syndrome and without mental retardation. Br J Dermatol 2001;144:363-8.
15. Altarescu G, Moore DF, Pursley R, et al. Enhanced endothelium- dependent vasodilatation in Fabry disease. Stroke 2001;32:1559-62.
16. Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002;33:525-31.
17. Schiffmann R, Murray GJ, Treco D, et al. Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 2000;97:365-70.
18. Eng CM, Banikazemi M, Gordon RE, et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001;68:711-22.